Funds › Silverarc Capital Management, LLC
Silverarc Capital Management, LLC
13F for Q3 2026, filed Nov 12, 2026. 63 positions worth $854.4M.Managers with more than $100 million in US-listed stocks list their holdings each quarter, within 45 days of quarter end. Long positions only: no short sales or cash.
Latest report
Q3 2026
filed Nov 12, 2026
Reported value
$854.4M
−$107.7M (11.2%) vs Q2 2026
Positions
63
65 in Q2 2026
Top 10 share
52.0%
of reported value
CheckedEach line's price per share is checked against other managers' reports of the same stock. Unit mix-ups are corrected. Reports no fix can rescue are left out.
Clean
prices match other managers' reports
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, what are the biggest new, added, trimmed and exited positions of Silverarc Capital Management, LLC in the latest 13F quarter?
Using 13F.ai, how has Silverarc Capital Management, LLC's portfolio concentration changed over the last four quarters?
Using 13F.ai, which of Silverarc Capital Management, LLC's top holdings have also been bought by insiders recently?
Connect your AI · Plans and the 7-day free trial (card required)
Holdings, Q3 2026
Largest first. Common shares only; puts and calls are under All positions.
| # | The fund's own figures at the end of the quarter. A report can be up to 45 days old when it is filed. Options and bonds are not counted here. | Filing | ||||
|---|---|---|---|---|---|---|
| 1 | KOD Kodiak Sciences Inc | 750,170 | $71.1M | 8.3% | +37.3% | 13F ↗ |
| 2 | CELC Celcuity Inc. | 803,193 | $63.9M | 7.5% | +60.3% | 13F ↗ |
| 3 | COGT Cogent Biosciences, Inc. | 1.57M | $50.4M | 5.9% | +23.0% | 13F ↗ |
| 4 | URGN UroGen Pharma Ltd. | 1.15M | $46.7M | 5.5% | -11.8% | 13F ↗ |
| 5 | IMNM Immunome, Inc. | 2.09M | $45.0M | 5.3% | +3.8% | 13F ↗ |
| 6 | GLUE Monte Rosa Therapeutics, Inc. | 3.11M | $37.1M | 4.3% | +181% | 13F ↗ |
| 7 | SGMT Sagimet Biosciences Inc. | 3.75M | $37.0M | 4.3% | +28.0% | 13F ↗ |
| 8 | ASND Ascendis Pharma A/S | 152,175 | $34.7M | 4.1% | -26.2% | 13F ↗ |
| 9 | RYTM Rhythm Pharmaceuticals, Inc. | 348,317 | $33.2M | 3.9% | +11.8% | 13F ↗ |
| 10 | BIIB Biogen Inc. | 112,790 | $25.5M | 3.0% | +134% | 13F ↗ |
| 11 | IMVT Immunovant, Inc. | 624,055 | $21.1M | 2.5% | +0.8% | 13F ↗ |
| 12 | DNTH Dianthus Therapeutics, Inc. | 236,582 | $20.8M | 2.4% | -39.3% | 13F ↗ |
| 13 | ORKA Oruka Therapeutics, Inc. | 247,918 | $20.6M | 2.4% | -29.7% | 13F ↗ |
| 14 | ERAS Erasca, Inc. | 1.33M | $19.5M | 2.3% | +5.3% | 13F ↗ |
| 15 | ABVX Abivax SA · ADR | 175,699 | $17.4M | 2.0% | +3.6% | 13F ↗ |
| 16 | CLDX Celldex Therapeutics, Inc. | 487,589 | $15.8M | 1.8% | New | 13F ↗ |
| 17 | OVID Ovid Therapeutics Inc. | 5.95M | $14.8M | 1.7% | +91.9% | 13F ↗ |
| 18 | SYRE Spyre Therapeutics, Inc. | 151,151 | $13.5M | 1.6% | +152% | 13F ↗ |
| 19 | DFTX Definium Therapeutics, Inc. | 345,946 | $13.2M | 1.5% | -13.5% | 13F ↗ |
| 20 | HLXC Helix Acquisition Corp. III | 1.21M | $12.8M | 1.5% | +2.6% | 13F ↗ |
| 21 | ALKS Alkermes plc | 300,427 | $12.2M | 1.4% | +165% | 13F ↗ |
| 22 | CCCC C4 Therapeutics, Inc. | 3.45M | $11.5M | 1.3% | +13.9% | 13F ↗ |
| 23 | AVLN Avalyn Pharma Inc. | 378,352 | $10.8M | 1.3% | +14.5% | 13F ↗ |
| 24 | CERS Cerus Corporation | 3.95M | $9.4M | 1.1% | +13.8% | 13F ↗ |
| 25 | ALXO ALX Oncology Holdings Inc. | 6.57M | $9.1M | 1.1% | +14.3% | 13F ↗ |
| 26 | ZBIO Zenas BioPharma, Inc. | 334,057 | $9.0M | 1.1% | -34.5% | 13F ↗ |
| 27 | CMPS COMPASS Pathways Plc · ADR | 717,356 | $8.9M | 1.0% | +42.5% | 13F ↗ |
| 28 | RNAQU Rainier Acquisition Corporation Units · Units | 853,875 | $8.7M | 1.0% | New | 13F ↗ |
| 29 | CGEN Compugen Ltd. | 3.59M | $8.5M | 1.0% | +12.6% | 13F ↗ |
| 30 | SVRA Savara, Inc. | 1.52M | $7.8M | 0.9% | +12.1% | 13F ↗ |
| 31 | PCVX Vaxcyte, Inc. | 125,080 | $7.1M | 0.8% | -13.7% | 13F ↗ |
| 32 | YARW Yarrow Bioscience, Inc. | 301,919 | $6.8M | 0.8% | New | 13F ↗ |
| 33 | IBIO iBio, Inc. | 5.36M | $6.3M | 0.7% | +52.2% | 13F ↗ |
| 34 | ARCT Arcturus Therapeutics Holdings Inc. | 459,899 | $6.3M | 0.7% | New | 13F ↗ |
| 35 | PRAX Praxis Precision Medicines, Inc. | 19,753 | $5.8M | 0.7% | -69.9% | 13F ↗ |
| 36 | KNSA Kiniksa Pharmaceuticals International, plc | 75,697 | $5.6M | 0.7% | New | 13F ↗ |
| 37 | ELVN Enliven Therapeutics, Inc. | 121,452 | $5.6M | 0.7% | -75.2% | 13F ↗ |
| 38 | SLDB Solid Biosciences Inc. | 760,337 | $5.5M | 0.6% | +13.7% | 13F ↗ |
| 39 | EVMN Evommune, Inc. | 594,027 | $4.9M | 0.6% | New | 13F ↗ |
| 40 | SNDX Syndax Pharmaceuticals, Inc. | 247,418 | $4.7M | 0.5% | -79.6% | 13F ↗ |
| 41 | BNTC Benitec Biopharma Inc. | 443,109 | $4.4M | 0.5% | -34.8% | 13F ↗ |
| 42 | RACC Research Alliance Corporation III | 404,728 | $4.4M | 0.5% | +12.4% | 13F ↗ |
| 43 | BLSM BlossomHill Therapeutics, Inc. | 202,104 | $3.8M | 0.4% | New | 13F ↗ |
| 44 | FTH Faeth Therapeutics, Inc. | 124,098 | $3.7M | 0.4% | New | 13F ↗ |
| 45 | ABEO Abeona Therapeutics Inc. | 693,441 | $3.6M | 0.4% | +13.6% | 13F ↗ |
| 46 | RACD Research Alliance Corporation IV | 301,962 | $3.5M | 0.4% | New | 13F ↗ |
| 47 | ANL Adlai Nortye Group Ltd. · ADR | 216,617 | $3.5M | 0.4% | New | 13F ↗ |
| 48 | PALI Palisade Bio, Inc. | 2.34M | $3.2M | 0.4% | New | 13F ↗ |
| 49 | IRON Disc Medicine, Inc. | 47,312 | $3.1M | 0.4% | -42.9% | 13F ↗ |
| 50 | TELA TELA Bio, Inc. | 2.14M | $2.5M | 0.3% | Unchanged | 13F ↗ |
Showing the top 50 of 63 positions. Premium lists every position, plus puts and calls.
Changes since Q2 2026
15 new, 26 added to, 20 trimmed, 17 exited, 2 unchanged. By estimated dollars.
New positions (15)
| CLDX Celldex Therapeutics, Inc. | 487,589 | New | $15.8M |
| RNAQU Rainier Acquisition Corporation Units · Units | 853,875 | New | $8.7M |
| YARW Yarrow Bioscience, Inc. | 301,919 | New | $6.8M |
| ARCT Arcturus Therapeutics Holdings Inc. | 459,899 | New | $6.3M |
| KNSA Kiniksa Pharmaceuticals International, plc | 75,697 | New | $5.6M |
| EVMN Evommune, Inc. | 594,027 | New | $4.9M |
| BLSM BlossomHill Therapeutics, Inc. | 202,104 | New | $3.8M |
| FTH Faeth Therapeutics, Inc. | 124,098 | New | $3.7M |
| RACD Research Alliance Corporation IV | 301,962 | New | $3.5M |
| ANL Adlai Nortye Group Ltd. · ADR | 216,617 | New | $3.5M |
Added to (26)
| CELC Celcuity Inc. | 803,193 | +60.3% | $24.0M |
| GLUE Monte Rosa Therapeutics, Inc. | 3.11M | +181% | $23.9M |
| KOD Kodiak Sciences Inc | 750,170 | +37.3% | $19.3M |
| BIIB Biogen Inc. | 112,790 | +134% | $14.6M |
| COGT Cogent Biosciences, Inc. | 1.57M | +23.0% | $9.4M |
| SYRE Spyre Therapeutics, Inc. | 151,151 | +152% | $8.1M |
| SGMT Sagimet Biosciences Inc. | 3.75M | +28.0% | $8.1M |
| ALKS Alkermes plc | 300,427 | +165% | $7.6M |
| OVID Ovid Therapeutics Inc. | 5.95M | +91.9% | $7.1M |
| RYTM Rhythm Pharmaceuticals, Inc. | 348,317 | +11.8% | $3.5M |
Trimmed (20)
| SNDX Syndax Pharmaceuticals, Inc. | 247,418 | -79.6% | -$18.2M |
| ELVN Enliven Therapeutics, Inc. | 121,452 | -75.2% | -$16.9M |
| DNTH Dianthus Therapeutics, Inc. | 236,582 | -39.3% | -$13.5M |
| PRAX Praxis Precision Medicines, Inc. | 19,753 | -69.9% | -$13.4M |
| ASND Ascendis Pharma A/S | 152,175 | -26.2% | -$12.3M |
| ACRS Aclaris Therapeutics, Inc. | 238,541 | -87.7% | -$9.0M |
| ORKA Oruka Therapeutics, Inc. | 247,918 | -29.7% | -$8.7M |
| ORIC Oric Pharmaceuticals, Inc. | 160,552 | -78.3% | -$7.8M |
| URGN UroGen Pharma Ltd. | 1.15M | -11.8% | -$6.2M |
| ZBIO Zenas BioPharma, Inc. | 334,057 | -34.5% | -$4.7M |
Exited (17)
| VCYT Veracyte, Inc. | 318,001 | Exited | -$18.7M |
| GH Guardant Health, Inc. | 99,826 | Exited | -$15.0M |
| TRVI Trevi Therapeutics, Inc. | 678,095 | Exited | -$12.6M |
| MANE Veradermics, Incorporated | 95,000 | Exited | -$11.7M |
| XENE Xenon Pharmaceuticals Inc. | 186,821 | Exited | -$11.3M |
| AVTX Avalo Therapeutics, Inc. | 500,402 | Exited | -$9.2M |
| WGS GeneDx Holdings Corp. | 122,269 | Exited | -$8.4M |
| ARTV Artiva Biotherapeutics, Inc. | 525,000 | Exited | -$5.1M |
| INSM Insmed Incorporated · Com Par $.01 | 34,438 | Exited | -$3.7M |
| KPTI Karyopharm Therapeutics Inc. | 297,460 | Exited | -$2.9M |
The 10 largest of each, by estimated dollars: shares changed times the later report's price. Index tracking, splits and mergers move positions too.
All positions
Search, sort and filter every position, with puts and calls on their own tab. Premium plan.
Every position, puts and calls. Part of Premium.
Compare two quarters
Pick any two quarters: what is new, added to, trimmed or exited. Premium plan.
Any two quarters side by side. Part of Premium.
Reported value by quarter
Value and number of positions at the end of each quarter.
Loading…
Largest positions in earlier quarters
Pick a quarter to see what the fund's biggest positions were then.
Loading…
Ten largest positions
By value, Q3 2026.
Filings
| Filing | ||||||
|---|---|---|---|---|---|---|
| Q3 2026 | Nov 12, 2026 | 13F-HR | 70 | $854.4M | Current | SEC ↗ |
| Q2 2026 | Aug 13, 2026 | 13F-HR | 73 | $962.2M | Current | SEC ↗ |
| Q1 2026 | May 14, 2026 | 13F-HR | 73 | $979.8M | Current | SEC ↗ |
| Q4 2025 | Feb 12, 2026 | 13F-HR | 68 | $720.1M | Current | SEC ↗ |
| Q3 2025 | Nov 12, 2025 | 13F-HR | 82 | $741.6M | Current | SEC ↗ |
| Q2 2025 | Aug 14, 2025 | 13F-HR | 65 | $542.3M | Current | SEC ↗ |
| Q1 2025 | May 14, 2025 | 13F-HR | 69 | $489.0M | Current | SEC ↗ |
Most recent first, up to 80. An amendment can replace a report or add holdings to it. All 13F filings
Information, not investment advice. Values are the fund's own figures at quarter end; a report can be up to 45 days old when filed. Disclaimer